Clinical Research Of High-throughput In Vitro Susceptibility Technology In Advanced Lung Cancer With Malignant Pleural Effusion

Objectives:Malignant pleural effusion will occur in almost all types of malignant tumors at the advanced stage,While the pleural metastasis of lung cancer is the most common cause of pleural effusion.accounting for about 40% of lung cancer.The emergence of malignant pleural effusion that prompts patients to lose the opportunity for surgical treatment,indicating a poor prognosis,life expectancy will be significantly shortened.Calculated from the establishment of the diagnosis,the median survival is only 3-12 months.At the same time malignant tumors has accumulated a large number of gene mutations in the disease development and treatment.Most patients are not sensitive to the routine use of chemotherapy.Also the conventional chemotherapy is not effective in the treatment of malignant pleural effusions.Therefore,we need a new type of treatment to solve this problem both from a clinical application point of view or from the basic research point of view.High-throughput in vitro susceptibility technology is using of the patient's own tumor cells.In the experiment we use automated procedures for large-scale rapid drug screening?analyze the data through the computer.We can select the sensitive drugs for the patient quickly.Pleural effusion in patients with advanced lung cancer often contain high purity of tumor cells.Therefore,we designed this trial to provide the best medication for the patients with advanced lung cancer.Materials and methods 12 samples of advanced lung cancer with malignant pleural effusion were selected.Extract more than 300 ml of pleural effusion sent to the Prece Do pharmaceuticals Co.Ltd.Lung cancer cells were cultured?purified,and the activity of the relevant drugs on lung cancer cells was tested on the high-throughput drug screening platform.At the same time calculate the inhibition rate.And organize the data for statistical analysis.Result There were 19 drugs that were sensitive to lung cancer cells(inhibition rate> 70%)at screening doses,the average inhibition rate from high to low is: Cinobufacini,Regorafenib,Topotecan,Doxorubicin,Triptolide,Apatinib,Mitoxantrone,Gemcitabine,Vandetanib,AZD9291,Sorafenib,Epirubicin,Paclitaxel,Erlotinib,Afatinib,Etoposide,Abiraterone,Gefitinib,Lapatinib.Among them,11 kinds of drugs with more than 90% inhibition rate were detected,including Cinobufotalin,Lapatinib,Adriamycin,Sorafenib,Regorafenib,Apatinib,Triptolide,Epirubicin,Erlotinib,Gefitinib,AZD9291,Six cases of Cinobufagin were more than 90% inhibition rate,Lapatinib,Sorafenib and Doxorubicin in 2 cases,the remaining drugs in 1 case.Conclusion High-throughput in vitro susceptibility technology;Advanced lung cancer;Inhibition rate;Malignant pleural effusion.